Mohsin Chowdhury, MD
Interventional Cardiology · Chesapeake, VANPI 1407267925
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (22.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.7%. Reporting peaked in 2021 at $5,087 and has fallen 87.6% since, to $632 in 2025.
Across 137 payments — averaging $105.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$3K
- Medtronic$3K
- Philips North America LLC$2K
- Boston Scientific$2K
- Edwards Lifesciences$2K
- Abbott$1K
- plus $2K from 25 others
What the payments were for
- Consulting fees$3,00021%
- Speaking & faculty fees$3,13822%
- Grants$1,1328%
- Travel & lodging$3,29423%
- Food & beverage$3,23822%
- Education$7195%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 1 | $3,000 |
| Medtronic(2 entities) | 19 | $2,794 |
| Philips North America LLC | 6 | $2,124 |
| Boston Scientific | 8 | $1,760 |
| Edwards Lifesciences | 9 | $1,524 |
| Abbott | 9 | $1,414 |
| Novartis | 20 | $322 |
| Astellas Pharma US Inc | 2 | $200 |
| Johnson & Johnson | 10 | $184 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $145 |
| Boehringer Ingelheim | 6 | $136 |
| Cvrx, Inc. | 2 | $128 |
| Amgen | 6 | $122 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Pfizer | 4 | $64 |
| Heartflow, Inc. | 1 | $57 |
| Abiomed | 2 | $52 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Baxter Healthcare | 2 | $47 |
| Cardinal Health 200 LLC | 1 | $42 |
| Bridgebio Pharma, Inc. | 2 | $37 |
| Opsens Inc. | 1 | $33 |
| Cook Medical LLC | 2 | $27 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Bayer | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Shockwave Medical, Inc | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,520 in reported general payments places this provider in the 75th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $104,567 |
| EntrestoSacubitril/Valsartan | 19 | $30,820 |
| XareltoRivaroxaban | 22 | $22,881 |
| JardianceEmpagliflozin | 12 | $17,515 |
| BrilintaTicagrelor | 11 | $13,285 |
| Metoprolol Succinate | 143 | $1,937 |
| Prasugrel Hcl | 20 | $1,552 |
| Atorvastatin Calcium | 131 | $1,416 |
| ClopidogrelClopidogrel Bisulfate | 83 | $1,119 |
| Carvedilol | 118 | $1,012 |
| Ezetimibe | 23 | $943 |
| Losartan Potassium | 92 | $822 |
| Rosuvastatin Calcium | 62 | $774 |
| Amlodipine Besylate | 88 | $557 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 42 | $518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $104,567115 claims |
| NovartisEntresto | $322 | $30,82019 claims |
| Johnson & JohnsonXarelto | $184 | $22,88122 claims |
| Boehringer IngelheimJardiance | $136 | $17,51512 claims |
| AstraZenecaBrilinta | $21 | $13,28511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Chesapeake
- Dhananjai MenziesChesapeake$43K
- Ashesh BuchChesapeake$14K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
- Jeremy BockLeesburg$202K
- Wayne BatchelorFalls Church$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.